Published in Hepatitis Weekly, April 4th, 2005
The first patent, titled "Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double-Stranded RNA" (AU patent No. 776150), covers the use of synthetically produced as well as DNA-encoded double-stranded RNA in vertebrates for attenuation of gene expression (RNA interference). The claims cover the use of RNAi in vertebrate cell culture and animals, as well as RNAi-based human therapeutics.
The second patent, titled "Composition and Method for In Vivo and In Vitro...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.